Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the FirmNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (
NYSECPRI), Caribou Biosciences, Inc.
NASDAQ: CRBUNASDAQCRBU)
(NASDAQ:NXTNASDAQNXT
, and Transocean Ltd. (NYSE: RIGNYSE
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Caribou, FTAI, and Revance and Encourages Investors to Contact the FirmNEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (
NASDAQBIOA), Caribou Biosciences, Inc.
NASDAQ: CRBUNASDAQCRBU)
(NASDAQ:FTAINASDAQFTAI
, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou BiosciencesFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the FirmNEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (
NYSECPRI), Caribou Biosciences, Inc.
NASDAQ: CRBUNASDAQCRBU)
(NASDAQ:NXTNASDAQNXT
, and Transocean Ltd. (NYSE: RIGNYSE
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou BiosciencesFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025 - CRBUFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, BioAge, and Transocean and Encourages Investors to Contact the FirmNEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (
NYSECPRI), Caribou Biosciences, Inc.
NASDAQ: CRBUNASDAQCRBU)
(NASDAQ: BIOANASDAQBIOA
, and Transocean Ltd. (NYSE: RIGNYSE
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Caribou Biosciences, Inc. Shareholders are Encouraged to Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the CRBU Class ActionSAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (
NASDAQCRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or “the Company”) (
NASDAQCRBU) and certain of its officers.
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare ConferenceBERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
CARIBOU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the FirmNEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) (
NASDAQCRBU) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”). Investors have until February 24, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Stockholder Notice: Robbins LLP Informs Stockholders of Caribou Biosciences, Inc. of the Class Action LawsuitSAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (
NASDAQCRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.
Caribou Biosciences Appoints Sri Ryali as Chief Financial OfficerBERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or “the Company”) (
NASDAQCRBU) and certain of its officers.
Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Caribou Biosciences, Inc. (
NASDAQCRBU) securities between July 14, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Caribou is a clinical-stage biopharmaceutical company.
Caribou Biosciences to Participate in Upcoming Investor ConferencesBERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 --
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC.
